NASDAQ : IAM
Iambic Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 13.43 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 636.59M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 636.59M |
| Enterprise Value | 433.94M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 47.40M |
| Shares Outstanding | 47.40M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.41% |
| Owned by Institutions (%) | n/a |
| Float | 4.93M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.88 |
| Forward PS | n/a |
| PB Ratio | 3.94 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 23.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.59 |
| Quick Ratio | 4.51 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,706.62 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -53.13% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $106,731 |
| Profits Per Employee | -$551,146 |
| Employee Count | 171 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 47,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,016,617 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 18.25M |
| Gross Profit | -83.49M |
| Operating Income | -100.19M |
| Pretax Income | -94.20M |
| Net Income | -94.25M |
| EBITDA | -98.81M |
| EBIT | -100.19M |
| Loss Per Share | -$4.27 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 207.88M |
| Total Debt | 5.23M |
| Net Cash | 202.65M |
| Net Cash Per Share | $4.28 |
| Equity (Book Value) | 161.48M |
| Book Value Per Share | -9.85 |
| Working Capital | 174.77M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -65.73M |
| Capital Expenditures | -2.44M |
| Depreciation & Amortization | 1.38M |
| Net Borrowing | -98,000 |
| Free Cash Flow | -68.17M |
| FCF Per Share | -$1.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -548.93% |
| Pretax Margin | -516.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -31.80% |
| FCF Yield | -10.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.88 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |